IQVIA and Kexing Biopharm expand strategic collaboration to accelerate global biosimilar development using ai-enabled capabilities.

{
  "signal_id": "89ac0710-ef72-486a-8f6b-789077fc83e9",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-05-13T20:30:00+00:00",
  "company": {
    "name": "IQVIA",
    "domain": "iqvia.com"
  },
  "data": {
    "url": "https://www.pharmaceutical-tech.com/pressreleases/iqvia-and-kexing-biopharm-expand-strategic",
    "title": "IQVIA and Kexing Biopharm expand strategic collaboration to accelerate global biosimilar development using ai-enabled capabilities.",
    "ticker": "NYSE:IQV",
    "excerpt": "IQVIA and Kexing Biopharm expand strategic collaboration to accelerate global biosimilar development using ai-enabled capabilities.\n\n15 May 2026\n\nIQVIA, a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, is advancing its strategic collaboration with Kexing Biopharm to support a global, multi-product biosimilar development and commercialization program. Kexing Biopharm (Stock Code: 688136.SH) is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production and sales of recombinant protein drugs and microecological preparations.\n\nThe collaboration is designed to support Kexing's global expansion by bringing together IQVIA's end-to-end capabilities across the development lifecycle. By aligning clinical development, regulatory strategy, advanced analytics and commercialization under a coordinated global approach, the program aims to accelerate biosimilar development for international markets while upholding rigorous standards for quality and scientific integrity.\n\nIn parallel, the collaboration integrates IQVIA's AI-enabled clinical trial capabilities to enhance speed, efficiency and confidence in decision-making throughout development. The use of AI across key activities - from protocol design to site identification and study conduct - will help streamline...",
    "summary": "IQVIA Inc partners with Kexing Biopharm Co..",
    "location": "Durham, North Carolina, United States, Northern America, Americas",
    "planning": false,
    "image_url": "https://industry.pharmaceutical-tech.com/slider/large_1778764173-cphi-americas-media-partner.webp",
    "confidence": 0.4134,
    "published_at": "2026-05-15T00:00:00Z",
    "location_data": [
      {
        "city": "Durham",
        "state": "North Carolina",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "IQVIA, a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, is advancing its strategic collaboration with Kexing Biopharm to support a global, multi-product biosimilar development and commercialization program.",
    "related_company_name": "Kexing Biopharm Co.",
    "related_company_domain": "kexingbiopharm.com"
  }
}

curl https://signals.autobound.ai/v1/signals/89ac0710-ef72-486a-8f6b-789077fc83e9 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"iqvia.com","limit":20}'